Suppr超能文献

恶性胶质瘤的快中子治疗——日本国立放射科学研究所的研究结果

Fast neutron therapy for malignant gliomas--results from NIRS study. National Institute of Radiological Sciences.

作者信息

Mizoe J E, Aoki Y, Morita S, Tsunemoto H

机构信息

National Institute of Radiological Sciences, Chiba, Japan.

出版信息

Strahlenther Onkol. 1993 Apr;169(4):222-7.

PMID:8387697
Abstract

The results of combined radiotherapy with fast neutrons and photons for 39 malignant gliomas were analyzed. The patients consisted of 16 astrocytoma grade 3 and 23 glioblastoma multiforme. There were two kinds of combination methods which were either "boost therapy" or "mixed beam therapy" with a localized fast neutron field. The average dose of fast neutrons was 569 cGy (n, gamma) and that of photons was 36.86 Gy. The median survival of astrocytoma grade 3 was 15.5 months, and that of glioblastoma multiforme was also 15.5 months. With respect to the combination methods, there was no difference between the boost regimen and the mixed beam regimen. This result seems to have no impact on survival compared to other reports. Patients' ages, surgical debulking procedures, and photon doses were listed as significant prognostic factors, but doses of fast neutrons had no prognostic significance for survival. Because there were no moderate or severe complications for the brain except permanent epilation in all cases, neutron dose escalation study with a localized field will be recommended.

摘要

分析了39例恶性胶质瘤患者接受快中子与光子联合放疗的结果。患者包括16例3级星形细胞瘤和23例多形性胶质母细胞瘤。有两种联合方法,即“强化治疗”或局部快中子野的“混合束治疗”。快中子的平均剂量为569 cGy(n,γ),光子的平均剂量为36.86 Gy。3级星形细胞瘤的中位生存期为15.5个月,多形性胶质母细胞瘤的中位生存期也为15.5个月。关于联合方法,强化方案和混合束方案之间没有差异。与其他报告相比,这一结果似乎对生存期没有影响。患者年龄、手术减瘤程序和光子剂量被列为重要的预后因素,但快中子剂量对生存期没有预后意义。由于除所有病例均出现永久性脱发外,脑部无中度或重度并发症,因此建议进行局部野中子剂量递增研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验